

August 19, 2019

VIA EDGAR

United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

**Re: Xeris Pharmaceuticals, Inc.
Acceleration Request for Registration Statement on Form S-3
File No. 333-233061**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “**Act**”), Xeris Pharmaceuticals, Inc. (the “**Company**”) hereby requests that the effective date of the above-referenced registration statement (the “**Registration Statement**”) be accelerated to August 21, 2019, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

If you have any questions regarding this request, please contact Joseph Theis of Goodwin Procter LLP at (617) 570-1928.

Sincerely,

XERIS PHARMACEUTICALS, INC.

/s/ Barry Deutsch

Barry Deutsch
Chief Financial Officer

cc: Barry Deutsch, Chief Financial Officer, *Xeris Pharmaceuticals, Inc.*
Joseph Theis, Jr., Esq., *Goodwin Procter LLP*